Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT02575066 2019-06-27

PASART-2

Phase 2 Terminated

25 enrolled

Sarcoma

NCT01855724 2018-11-07

Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer

Phase 2 Terminated

29 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Genitourinary

Carcinoma, Renal Cell

NCT01394211 2018-07-26

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02113826 2017-11-06

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Phase 2 Terminated

6 enrolled

Sarcoma

Sarcoma, Alveolar Soft Part

NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Phase 2 Terminated

7 enrolled 8 charts

CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01622660 2017-08-22

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2 Terminated

2 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02089802 2017-08-18

OPERA

Phase 2 Terminated

6 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Phase 2 Terminated

25 enrolled 7 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01059656 2016-07-01

DFSP-PAZO

Phase 2 Terminated

23 enrolled

Sarcoma

Dermatofibrosarcoma

NCT01080248 2015-06-09

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Phase 2 Terminated

2 enrolled 5 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00549328 2014-11-19

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01313663 2014-10-27

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Phase 2 Terminated

20 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01049776 2014-09-19

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Phase 2 Terminated

32 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00945477 2013-11-18

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Phase 2 Terminated

11 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

Pazopanib Maintenance Phase II

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

EVA

NIVOSWITCH

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

NOPASS

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

HYPAZ

PASART-2

Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

OPERA

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

DFSP-PAZO

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade